Abstract library

113 results for "90Y".
#1154 Selective Internal Radiation Therapy (SIRT) Radioembolisation with 90 Yttrium in Patients with Unresectable Liver Neuroendocrine Metastases in a Specialized Center. An Initial Report
Introduction: Most patients with neuroendocrine tumors present liver metastases at some point of the clinical course. Liver directed treatment, such as 90 Yttrium is a method of treatment used in patients with non-resectable liver lesions, which is effective in the control of symptoms and tumor growth.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Juan Manuel O'Connor
#2013 Optimizing Reconstruction Algorithm to Improve Quality of Post-PRRT Yittrium-90 PET Scan
Introduction: 90Y is commonly used in PRRT for NET. It has no gamma photon in its emission that significantly limits post-therapy imaging and dosimetry. Other than Bremsstrahlung imaging which bears hereditary drawbacks of poor resolution, PET scan has been used for post-PRRT imaging. However, in daily clinical practice, due to extremely low abundance of positron emission per decay and patient’s intolerability of prolonged scan time, it is very difficult to obtain a scan with decent quality.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Doctor Sean X Yan
Authors: Yan S X, Lim G K, ...
#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience
Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Merav Fraenkel
#14 Radioguided surgery in NET: First impression with Ga-68 labeled somatostatin analogues
Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#22 A Case Illustrative of Phenotypic Heterogeneity and Challenges in the Management of Paraganglioma
Introduction: Paragangliomas (PGLs) are extra-adrenal, usually benign, highly vascularized tumors that originate from neural-crest-derived chromaffin cells. These tumors are subdivided as either sympathetic or parasympathetic, depending on their location and catecholamine production. Sympathetic PGLs are situated along the abdominal sympathetic trunk and usually produce catecholamines, whereas parasympathetic PGLs are located in the head and neck, and these usually do not produce catecholamines. PGLs may present as sporadic or inherited tumor syndrome, including MEN 2, with RET germline mutations, von Hippel-Lindau (VHL) disease due to germline mutations in VHL gene, and pheochromocytoma-PGL syndrome. The latter is frequently a hereditary condition and is caused by germline mutations in the SDHB, SDHC, or SDHC genes. Patients with familial PGLs may present at a younger age, often as multifocal tumors, with an increased risk of recurrence and a higher frequency of malignancy in those with SDHB mutations. SDH mutations induce angiogenesis and tumorogenesis through the inhibition of hypoxia-inducible factors (HIF)-propyl hyroxylase. A younger age at onset, malignancy, and a positive family history are clinical parameters of high specificity, but low sensitivity for diagnosis. Genetic analysis for mutations in SDH genes for the patient and family members, and surveillance for the affected patient and family members, are necessary where there are no clear clinical or family indicators for the syndrome. We present a case of a large abdominal malignant PGL in a 20-year-old pt. that went on without clinical detection for at least three years.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohammed Ahmed
#23 Developing a customized database for NET in a developing country
Introduction: The establishment of a neuroendocrine registry is extremely hard in developing countries. Many patients miss follow-up after surgical procedures and many die in different hospitals with a distinct national security health system number. As in any developing country, Brazil has a large movement of people to urban areas, making the tracking of former addresses impossible for patients who were treated some years prior. Therefore, it is more feasible to evaluate a demographic distribution of neuroendocrine tumors by topography or histological subtype, but the analysis of clinical events, such as progression-free survival, disease-free survival, time to progression or overall survival, is compromised.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: PhD Bernardo Garicochea
#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust
Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Teo L, Hearn K, Bernstone G, Wright R, ...
#39 Specialist dietetic input and nutritional outcomes in Neuroendocrine Tumour Patients
Introduction: Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that are complex to manage and require a multidisciplinary approach. The most common primary sites are the small intestine and pancreas. The disease itself, as well as sequelae from surgery and medical therapy, can have a negative impact on patients’ nutritional status. Weight loss is known to be a poor prognostic indicator.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MRS CALEY L SCHNAID
Authors: Schnaid C, Khan M, Davies P, Jamieson A, ...
#58 Surgical approaches in 84 patients with insulinomas in multiple endocrine neoplasia type 1 (MEN 1)
Introduction: Management of insulinomas in the setting of Multiple Endocrine Neoplasia type 1 (MEN1) remains controversial.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Delphine Vezzosi
#65 Deletions of 11q21-q25 are associated with atypical lung carcinoids and a poor clinical outcome
Introduction: Lung carcinoids comprise a group of smoking-unrelated neuroendocrine tumors, which can be classified in typical (TC) and atypical (AC) carcinoids. Classification is complex and its accuracy to predict disease outcome is variable. In a previous array comparative genomic hybridization (arrayCGH) study, we showed that the average number of chromosomal alterations (≥ 1Mb) was significantly higher in ACs than in TCs (512 v. 226 per tumor) and that the most common region of chromosome loss was 11q21-q25 (Neuroendocrinology 2009;90:136-137).
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MSc Dorian RA Swarts